Market Tracker

07/01 4:47pm ET

Repligen Corp (NASDAQ:RGEN)

27.97
Delayed Data
As of 4:00pm ET
 +0.61 / +2.23%
Today’s Change
20.07
Today|||52-Week Range
42.22
-1.13%
Year-to-Date
Repligen (RGEN) in Focus: Stock Adds 6.9% in Session
Jun 30 / Zacks.com - Paid Partner Content
Brexit Bargains Beckon the Brave
Jun 26 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close27.36
Today’s open27.42
Day’s range26.64 - 28.00
Volume431,936
Average volume (3 months)322,875
Market cap$920.4M
Dividend yield--
Data as of 4:00pm ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)+12.00%
Earnings growth (this year)+67.86%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+31.45%
P/E ratio116.8
Price/Sales11.37
Price/Book7.34

Competitors

 Today’s
change
Today’s
% change
INSYINSYS Therapeutics I...+0.53+4.10%
SRPTSarepta Therapeutics...+1.18+6.19%
CLLSCellectis SA+0.66+2.48%
MGNXMacroGenics Inc+0.20+0.74%
Data as of 4:00pm ET, 07/01/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)$0.13
Annual revenue (last year)$83.5M
Annual profit (last year)$9.3M
Net profit margin11.19%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Tony J. Hunt
Vice President-
Global Operations
Steve Curran
Corporate headquarters
Waltham, Massachusetts

Forecasts